A simple non-lysis detection of empty vs. full AAV capsids in real time
In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.
Adeno-associated virus (AAV) vectors are the leading platform for gene delivery in the treatment of various human diseases. During development, AAV in-process samples often yield mixed populations of particles, including full capsids, partially full capsids and empty capsids. This heterogeneity necessitates efficient product characterization to establish the empty-to-full capsid ratios. These ratios can vary dramatically in vector preparations produced by standard transient transfection production pipelines, highlighting the need for suitable analytical characterization methods.
While many techniques have been deployed to detect these ratios, they are often expensive, time-consuming and present various other challenges, making it difficult for developers to identify an ideal, cost-effective technique. Sartorius’ AAVX biosensor was developed to enable rapid, real-time and high-throughput measurement of AAV capsid titer in samples across the AAV bioprocess workflow, facilitating quick process optimization, quality checks and increased productivity.
This novel method significantly extends the capability of AAVX biosensors by advancing the accurate and efficient determination of empty-to-full capsid ratios. This rapid, cost-effective, high-throughput solution addresses the critical need for precise product characterization in AAV vector production, enhancing process optimization and ensuring higher-quality outcomes in gene therapy.
What will you learn?
- Understanding AAV heterogeneity: gain insights into the mixed populations of AAV particles and the importance of characterizing empty-to-full capsid ratios
- Challenges in current techniques: learn about the limitations of existing methods for detecting capsid ratios, including cost, time and efficiency issues
- Introduction to AAVX biosensor: discover how Sartorius’ AAVX biosensor enables rapid, real-time and high-throughput measurement of AAV capsid titer
- Innovative non-lysis method: explore the proposed method that extends the use of AAVX biosensors for determining empty-to-full capsid ratios without the need for capsid lysis
- Applications and benefits: understand the practical applications of this method in process optimization, quality checks and productivity enhancement in AAV bioprocess workflows
Who this may interest?
- Gene therapy researchers involved in the development and optimization of gene therapy treatments
- Bioprocess engineers focused on the production and characterization of viral vectors
- Quality control specialists responsible for ensuring the quality and consistency of biopharmaceutical products
- Academic researchers studying viral vector technology and its applications in gene therapy
- Anyone engaged in the production and commercialization of gene therapy products
Speaker
David Apiyo
Manager of Application Development
Sartorius (Göttingen, Germany)
David is currently Manager of BioAnalytics Applications Development at Sartorius and has more than 15 years of experience in label-free biomolecular interaction analysis. Before joining Sartorius, he was a Senior Scientist at Beckman Coulter (CA, USA). He obtained his PhD in Chemistry at Tulane University (LA, USA) and has held multiple Postdoctoral research positions.
This webinar was recorded on Tuesday 29 Ocotober 2024
In association with
